Epiomic Epidemiology Series: Wegener's Granulomatosis Forecast in 9 Major Markets 2015-2025

August 2015 | 42 pages | ID: E0409A81AC4EN
Black Swan Analysis limited

Abstracts

Wegener’s Granulomatosis (WG), also known as granulomatous with polyangiitis, is an autoimmune disease, involving necrotizing vasculitis associated with anti-neutrophil cytoplasm antibodies (ANCA). WG primarily involves the upper and lower respiratory tracts and kidneys and originates from an inherited genetic component coupled with an unknown environment stimulus. This report provides the current prevalent population for WG across 9 Major Markets (USA, France, Germany, Italy, Spain, UK, Brazil, Japan and India) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of WG have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities for WG include:

• Renal complications
• Other autoimmune conditions
• Respiratory complications
• Neurological complications
• Various vascular manifestations
• Deafness

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information form patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy

• Able to quantify patient populations in global WG’s market to target the development of future products, pricing strategies and launch plans.
• Gain further insight into the prevalence of WG and identify patient segments with high potential.
• Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
• Provide a level of understanding on the impact from specific co-morbid conditions on WG’s prevalent population.
• Identify sub-populations within WG which require treatment.
• Gain an understanding of the specific markets that have the largest number of WG patients.

Contents

Overview
Introduction
Cause of the Disease
Risk Factors & Prevention
Diagnosis of the Disease
Variation by Geography/Ethnicity
Disease Prognosis &Clinical Course
Key Co-morbid Conditions/Features Associated with the Disease
Methodology for Quantification of Patient Numbers
Top-Line Prevalence for Wegener’s Granulomatosis
Main Complications and Presenting Features of Wegener’s Granulomatosis
  Vascular Manifestations
  ANCA Serology Status
  Respiratory Complications of Wegner’s Granulomatosis
  ENT Features of Wegner’s Granulomatosis
  Neurological Features of Wegner’s Granulomatosis
  Renal Involvement of Wegner’s Granulomatosis
References
Appendix

List Of Tables

LIST OF TABLES & FIGURES

Prevalence of WG, total (000s)
Prevalence of WG, males (000s)
Prevalence of WG, females (000s)
WG by vascular manifestation, total (000s)
ANCA serology status at presentation for WG, total (000s)
Respiratory infiltrates & effusions in patients with WG, total (000s)
Presence of lung inflammation in patients with WG, total (000s)
ENT features at presentation of patients with WG, total (000s)
Neurological involvement at presentation of patients with WG, total (000s)
Presence of abnormal glomeruli in patients with WG, total (000s)
USA Prevalence of WG by 5-yr age cohort, males (000s)
USA Prevalence of WG by 5-yr age cohort, females (000s)
France Prevalence of WG by 5-yr age cohort, males (000s)
France Prevalence of WG by 5-yr age cohort, females (000s)
Germany Prevalence of WG by 5-yr age cohort, males (000s)
Germany Prevalence of WG by 5-yr age cohort, females (000s)
Italy Prevalence of WG by 5-yr age cohort, males (000s)
Italy Prevalence of WG by 5-yr age cohort, females (000s)
Spain Prevalence of WG by 5-yr age cohort, males (000s)
Spain Prevalence of WG by 5-yr age cohort, females (000s)
United Kingdom Prevalence of WG by 5-yr age cohort, males (000s)
United Kingdom Prevalence of WG by 5-yr age cohort, females (000s)
Brazil Prevalence of WG by 5-yr age cohort, males (000s)
Brazil Prevalence of WG by 5-yr age cohort, females (000s)
Japan Prevalence of WG by 5-yr age cohort, males (000s)
Japan Prevalence of WG by 5-yr age cohort, females (000s)
India Prevalence of WG by 5-yr age cohort, males (000s)
India Prevalence of WG by 5-yr age cohort, females (000s)